"That makes sense, since the American pediatric vaccine schedule now includes 48 vaccinations before the age of six," Stagliano says. "Parents are facing vaccination choice issues at every pediatric visit."
Fictional Fear Factors
In the brief filed by the groups with all the money from Wyeth and Pfizer, when warning that vaccine makers might flee the market if they have to face the threat of lawsuits and unpredictable litigation costs, they argue that the number of vaccine makers has not greatly increased since 1986 and refer to the "precarious state of the vaccine industry."
"The preemption of all design defect claims is critical to Congress's objective of stabilizing the vaccine market and safeguarding the Nation's vaccine supply," they claim.
First of all, the vaccine industry is not in dire financial straights, in fact far from it. On June 11, 2009, Kalorama Information issued a press release for the vaccine sales forecast in a market analysis report with the headline, "New Report Forecasts More Than Doubling of Vaccine Sales by 2013."
"Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has," Kalorama noted. The press release described 2008 as another "stellar year for the world vaccine market," in which sales "grew 21.5% since 2007 to reach $19.2 billion."
A year earlier, Kalorama reported that stronger than anticipated revenues for flu vaccines and the "surprising commercial success" of Merck's Gardasil had led to $16.3 billion in vaccine sales in 2007, "an increase of 38% over 2006 sales of $11.7 billion."
However: "Vaccine manufacturers face many challenges in bringing new vaccines to market," the amicus brief points out, with a note to: "See Paul A. Offit, Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?, 24 Health Affairs 622, 623-629 (2005)."
Next Page 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
1
1
1
